These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7670744)

  • 1. Therapy and clinical trials.
    Laker MF
    Curr Opin Lipidol; 1995 Aug; 6(4):U113-6. PubMed ID: 7670744
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of the coronary risk: is it enough to asses ApoB/ApoA1 ratio only or is plasma lipoprotein concentration still necessary?].
    Cybulska B
    Kardiol Pol; 2005 Feb; 62(2):153-6. PubMed ID: 15815801
    [No Abstract]   [Full Text] [Related]  

  • 3. Profiling a landmark clinical trial: Scandinavian Simvastatin Survival Study.
    Guptha S
    Curr Opin Lipidol; 1995 Oct; 6(5):251-3. PubMed ID: 8520845
    [No Abstract]   [Full Text] [Related]  

  • 4. Statins continue to be ubiquitous, but increasingly controversial.
    Sipkoff M
    Manag Care; 2008 Jun; 17(6):21-2. PubMed ID: 18624162
    [No Abstract]   [Full Text] [Related]  

  • 5. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
    Ballantyne CM
    Am Heart J; 2004 Jul; 148(1 Suppl):S3-8. PubMed ID: 15211326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What do the statin trials tell us?
    Waters DD
    Am J Manag Care; 2001 May; 7(5 Suppl):S138-43. PubMed ID: 11383375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy.
    Denke MA
    Circulation; 2005 Nov; 112(22):3368-70. PubMed ID: 16316961
    [No Abstract]   [Full Text] [Related]  

  • 8. Aggressive medical therapy for the prevention and treatment of coronary artery disease.
    Malloy MJ; Kane JP
    Adv Intern Med; 1997; 42():1-38. PubMed ID: 9048115
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating hypercholesterolemia aggressively.
    Wilson CS
    Nebr Med J; 1996 Jan; 81(1):3-4. PubMed ID: 8584066
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of coronary heart disease through cholesterol reduction.
    Grundy SM
    Am Fam Physician; 1997 May; 55(6):2250-8. PubMed ID: 9149652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fish oil supplements.
    Med Lett Drugs Ther; 2006 Jul; 48(1239):59-60. PubMed ID: 16841020
    [No Abstract]   [Full Text] [Related]  

  • 14. [Necessity of hypolipemic treatment in patients with coronary disease].
    Fernández-Miranda C; Aranda IL
    Med Clin (Barc); 1999 Mar; 112(11):438. PubMed ID: 10231779
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease.
    Farnier M; Volpe M; Massaad R; Davies MJ; Allen C
    Int J Cardiol; 2005 Jul; 102(2):327-32. PubMed ID: 15982505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1329-30. PubMed ID: 15297284
    [No Abstract]   [Full Text] [Related]  

  • 17. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin.
    Lye WC; Hughes K; Leong SO; Tan CC; Lee EJ
    Transplant Proc; 1995 Feb; 27(1):977-8. PubMed ID: 7879252
    [No Abstract]   [Full Text] [Related]  

  • 18. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
    Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
    Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoproteins AI and B as therapeutic targets.
    Charlton-Menys V; Durrington P
    J Intern Med; 2006 May; 259(5):462-72. PubMed ID: 16629852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
    MMW Fortschr Med; 2008 Jun; 150(23):39. PubMed ID: 18575369
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.